--- a
+++ b/clusters/3009knumclusters/clust_205.txt
@@ -0,0 +1,190 @@
+No prior pelvic radiation therapy
+Patients who have received prior pelvic radiotherapy
+Any prior pelvic radiation
+Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
+Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)
+Patients who have received previous vaginal, pelvic, or abdominal irradiation
+Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
+Patients who have received prior pelvic radiation or cytotoxic chemotherapy
+Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
+Subject who has received prior pelvic irradiation or is scheduled for pelvic nodal irradiation
+Previous pelvic radiation for prostate cancer.
+Prior pelvic radiotherapy or prostatectomy
+Radiation to spine/pelvis bone or chemoradiation to pelvic organs
+Plans for pelvic radiation while participating in the study
+Previous pelvic radiation for prostate cancer.
+Previous pelvic radiation
+Patients with any prior pelvic radiation therapy.
+Previous pelvic radiotherapy
+Prior pelvic or abdominal radiation
+Clinically large pelvic masses reaching above the umbilicus
+Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
+Pelvic organ prolapse greater than stage II
+Prior reconstructive pelvic surgery involving mesh for prolapse
+Patients who have previously been treated with talimogene laherparepvec, any other oncolytic virus or pelvic radiation are ineligible
+Histological or cytological confirmation of locally recurrent or metastatic rectal adenocarcinoma\r\n* Note: Patients with locally recurrent/persistent disease within the pelvis after primary therapy (chemotherapy, surgery, and/or radiotherapy) are eligible\r\n* Note: Patients who have had prior pelvic radiotherapy with a total dose of =< 54 Gy are eligible\r\n* Note: Patients with or without metastatic disease (excluding untreated central nervous system [CNS] metastasis), with primary pelvic disease or pelvic recurrence are eligible\r\n* Note: Patients with pelvic disease that is potentially resectable or unresectable are eligible
+Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy).
+No prior pelvic radiotherapy, chemotherapy, immunotherapy, or other anti-cancer treatment for rectal cancer
+Previous radiotherapy in the pelvic region (eg, prostate) or previous rectal surgery (eg, total mesorectal excision [TME]) or any investigational treatment for rectal cancer
+Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
+Has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Previous pelvic irradiation therapy
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Patients who have received previous vaginal, pelvic, or abdominal irradiation
+Prior history of abdominal irradiation; patients who have received prior pelvic radiation for colorectal cancer are eligible; however, prior radiation treatment plans must be reviewed prior to enrollment
+Prior pelvic radiation
+Rectal cancer staged as T4 by pelvic MRI
+Patients who have had pelvic or abdominal radiation therapy.
+Previous pelvic irradiation, prostate brachytherapy
+Eligible patients should not have had previous pelvic radiotherapy, chemotherapy or surgery for prostate cancer
+Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
+Previous pelvic RT
+Prior pelvic radiotherapy
+Previous pelvic radiation affecting >= 25% of the bone marrow; patients who received whole pelvic radiation are excluded
+Patients who had pelvic radiation within 12 months
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
+History of abdominal/pelvic radiation therapy
+Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
+Patients with any prior chemotherapy or radiotherapy for pelvic malignancy
+Previous pelvic radiation or prostate brachytherapy
+Candidate for pelvic or pelvic-inguinal radiotherapy and concurrent chemotherapy; patients undergoing preoperative chemoradiotherapy are excluded
+Prior history of hip, pelvic, or lumbosacral prosthesis or other implanted device
+Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
+Previous pelvic radiation for prostate cancer
+Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
+Previous chemotherapy or pelvic radiation therapy
+No prior pelvic radiation
+Tumour stage cT1-T3abN0 based on pelvic MRI
+cN0 stage based on pelvic MRI. Any nodes ? 10 mm in longest dimension are considered malignant, regardless of nodal morphology. For pelvic nodes < 10 mm in longest dimension, if nodes are seen and are deemed to be morphologically benign in the opinion of the radiologist and surgeon, the patient is eligible. Patients with visible pelvic sidewall nodes are excluded
+Previous pelvic radiation for any reason.
+Completion of pelvic radiotherapy treatment for this current rectal cancer or any prior pelvic radiotherapy (e.g., prior prostate or cervical cancer therapy).
+Prior pelvic radiotherapy
+Has known distant metastases; clinically involved pelvic nodes (N1-N3) are allowed
+Prior pelvic radiation
+Subjects who have a solitary central pelvic recurrence which can be curatively resected
+Any therapeutic pelvic radiation
+Subjects must not have had prior pelvic radiation therapy
+History of prior pelvic radiation therapy
+No prior pelvic radiation therapy or chemotherapy
+No prior pelvic radiotherapy
+Patients must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy, and radical cystectomy
+Previous systemic chemotherapy (for any cancer) or pelvic radiation therapy
+Previous pelvic radiation for bladder or prostate cancer if performed < 12 months prior to enrollment into the study
+Patients with a history of pelvic irradiation for any reason
+Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy or any pelvic or abdominal radiation for any prior malignancy
+Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
+Patients who have received prior pelvic irradiation are not eligible
+Received prior chemotherapy for any abdominal or pelvic tumor.
+Current or prior pelvic external beam radiotherapy within 5 years of entry
+Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded
+Any previous pelvic radiotherapy
+Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
+Subject who has undergone a prior pelvic anastomosis.
+Subject with an active abdominal or pelvic infection at the operation site.
+Patients must be planned to receive whole pelvic radiotherapy to a total dose of 45 Gy or greater
+Patients who received prior pelvic radiotherapy for any indication
+History of any major rectal or pelvic surgery or radiotherapy
+No previous history of pelvic radiation
+Patients with a history of prior whole pelvic radiation
+Pelvic radiation therapy
+Previous pelvic radiotherapy that would prevent prostate/seminal vesicle (SV) irradiation
+Patients who have received prior pelvic radiation
+Previous pelvic radiotherapy
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Prior history of pelvic radiation therapy
+History of prior chemotherapy or pelvic irradiation
+No history of previous pelvic irradiation
+History of prior pelvic irradiation
+Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
+Refuses or is unable to have pelvic MRI
+Subjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery for prostate cancer
+Prior history of pelvic radiotherapy
+Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
+Previous pelvic radiation for prior cancer
+Previous pelvic radiation therapy
+Prostate pelvic radiation within the past 12 months
+Prior pelvic radiation therapy
+Patients with isolated recurrences (vaginal, pelvic, or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery
+Recommended to undergo pelvic irradiation with concurrent chemotherapy
+An oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique)
+Patient must not have had radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Prior abdomino-pelvic irradiation
+Patients who have received previous vaginal, pelvic, or abdominal irradiation
+Prior pelvic irradiation.
+For abdominal or pelvic irradiation: active inflammatory bowel disease
+No history of previous chemotherapy or pelvic irradiation
+History of prior chemotherapy or pelvic irradiation
+Documented distant metastatic disease; but pelvic lymphoadenopathy is NOT excluded
+History of pelvic radiation
+E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
+Patients must not have undergone a prior partial cystectomy for invasive bladder cancer; patients must not have received any prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g. aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised
+Patients must not have received any prior pelvic irradiation
+Patients must be considered able to tolerate systemic chemotherapy and pelvic radiation therapy
+Previous pelvic radiation therapy
+Pelvic osseous tumors ANY SIZE
+Acute pelvic inflammatory disease
+Patients with a history of pelvic or abdominal radiotherapy;
+Patients must be at least 6 weeks out from pelvic irradiation, and must not have more than 10% of bone marrow irradiated.
+Has received and completed a course of pelvic radiotherapy ? 6 months prior to LAR surgery (Day 0).
+Candidate for pelvic, pelvic-inguinal, or extended field radiotherapy with or without concurrent chemotherapy; patients undergoing preoperative or adjuvant chemotherapy are excluded
+Radiation therapy to more than 25% of the bone marrow (note: whole pelvic radiation is considered to be over 25%)
+Previous pelvic irradiation, prostate brachytherapy
+Have had previous radiation of the pelvic area
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+No prior radiation to bladder or pelvic region
+Patients who have isolated recurrences (vaginal, pelvic, or paraaortic) that are amenable to potentially curative treatment with radiation therapy or surgery
+Patients who have pelvic irradiation with doses ? 45 Grays (Gy).
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Prior pelvic external beam radiotherapy (EBRT)
+Prior history of pelvic irradiation
+History of extensive prior pelvic irradiation.
+Patients with any prior history of whole pelvic radiation therapy (WPRT)
+Patients who have had previous pelvic radiation treatment
+Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
+Patients with any prior pelvic surgery
+Patients with prior history of pelvic fractures or hip replacement
+Large pelvic or intra-abdominal masses
+Participants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding 14 days
+Patients must have had a pelvic MRI within 28 days prior to the initiation of treatment
+History of previous abdominal or pelvic radiation therapy
+Prior breast, chest or pelvic radiotherapy
+Patients undergoing pelvic exenteration
+History of pelvic radiation
+Current diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam radiation therapy (RT) to the abdomen or pelvis to a minimum dose of 4500 cGy is planned
+Prior abdominal or pelvic RT
+Radiotherapy within 28 days and abdominal/pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1
+Patients cannot have previously received pelvic external beam radiation or brachytherapy; patients may be enrolled while undergoing vaginal brachytherapy radiation treatment
+Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
+History of prior abdominal or pelvic radiation
+Previously undergone major pelvic surgery
+Prior pelvic radiation
+Prior pelvic RT
+Known or suspected active pelvic infection
+Patients with prior abdominal or pelvic surgery
+Major abdominal or pelvic surgery within the past 6 months
+Prior pelvic radiation for any reason
+History of pelvic or rectal radiation therapy
+Subjects with previous pelvic or abdominal radiation therapy;
+Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation
+Willingness to undergo pelvic radiotherapy
+Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic radiation therapy [XRT])
+Extra-pelvic metastasis on any imaging or biopsy.
+Prior pelvic external beam radiation therapy (RT).
+SUB-STUDY I: Prior pelvic external beam radiation therapy or brachytherapy
+SUB-STUDY II: Prior pelvic external beam radiation therapy or brachytherapy
+Prior pelvic radiation
+Prior pelvic external beam radiation therapy or brachytherapy
+No prior pelvic radiotherapy
+Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of prior radiation, will be excluded from this investigation
+Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician
+Prior pelvic surgery or radiation
+Prior pelvic irradiation
+History of prior pelvic radiation
+Prior hip replacement or other major pelvic surgery
+Prior history of pelvic radiotherapy
+Prior history of pelvic radiation
+Past history of pelvic radiotherapy
+subjects with any contraindication to pelvic radiotherapy including, but not limited to, previous pelvic radiotherapy or brachytherapy
+Has received prior pelvic radiation therapy